Jurox says the reformulation will also help reduce waste associated with unpreserved ampule formulations and will help streamline portfolios with a requirement for only one buprenorphine listing.
Dr Dan Cripwell BSc (Hons) BVSc CertAVP (EM) CertAVP PgCert (VPS) MRCVS, Advanced Veterinary Practitioner and senior veterinary technical advisor at Jurox (UK) Limited, said: “I am delighted that Jurox can provide the UK veterinary market with this evolution of our multidose buprenorphine formulation. We constantly strive to provide the veterinary profession with first class clinical and technical support and our ability to perform in-house product research and development is also a great strength; this allows us to remain agile enough to make adaptations in an area where not much has changed in the past few years.
“In this instance, we were able to examine what improvements could be made to our existing drug portfolio and respond to the profession’s feedback with the redevelopment of the commonly utilised opioid analgesic, buprenorphine. Our hope is that, as well as the recent mixing claims added to the product licence, this development will encourage the best clinical use of the drug and, in turn, improve patient experience and outcome.”
For more information, contact your local Jurox account manager, phone 0800 500 3171, visit www.jurox.com/uk or email customerservice@jurox.co.uk.
Pfizer Animal Health and Central Veterinary Services are collaborating in a new venture to create a unified National Benchmarking Database open to all veterinary practices.
In what it says is an unprecedented move, Pfizer will integrate 15 years' worth of data from its Performance Index practice benchmarking service (formerly known as the Fort Dodge Index) with that of the Central Veterinary Services' Management Analysis Indices (MAI). These two benchmarking services have been in co-existence for a number of years, each using different databases. Combining the data from the participating practices within each benchmarking service will create a database of almost 300 practices, representing in excess of 10% of all UK companion animal and mixed practices. This, says the company, will provide a more accurate and relevant benchmarking of UK companion animal practice performance.
The first combined reports from this new National Database will be available in May providing a comprehensive analysis for the first quarter of 2012. For Performance Index practices, this will be available via a new web portal.
Participating practices will continue to access their reports and services independently via their respective portals for PI and MAI, but will benefit from the larger database providing greater accuracy, granularity and relevance of exactly who a practice chooses to benchmark itself against. This, in turn, should provide all participating practices with an even better understanding of both their critical success factors and where there are clear opportunities for growth. Pfizer says that as ever, practice data confidentiality will be guaranteed for all subscribing practices.
Ned Flaxman, Director Business Innovation, at Pfizer Animal Health said: "We have recognised that what veterinary practices really need is to be far more specific about who they benchmark themselves against. There is little relevance to a rural mixed practice in the Lake District employing 3 full time vets (FTVE) benchmarking themselves against a large 5 FTVE companion animal practice in the centre of Manchester - you are comparing apples and pears! My vision for creating the National Database was really to increase the business benefits of practice benchmarking and enable practices to compare apples with apples. With the new system, the large urban practice in Manchester should be able to compare its performance against other urban practices in the North of England employing 5FTVE!
"To ensure practices have accurate and relevant data from which to make informed decisions to grow and thrive in these turbulent conditions, the creation of a single national benchmarking database is the only sensible solution. Although we are effectively levelling the playing field by enabling other veterinary suppliers to offer benchmarking, we believe it is the right thing to do for veterinary practices and the market as a whole. For Pfizer Animal Health, the needs of our veterinary clients are the driving force for our business decisions, veterinary support services and product development."
Martin Barrow, Managing Director of Central Veterinary Services said: "We fully agree that a single benchmarking database is the right solution for the market. The creation of this National Database, open to all practices irrespective of their supplier, will provide the participants with unique tools to give them powerful insights for their practices' future continued success.
"MAI and the Performance Index have competed with each other for years and provided a very useful added value service for their respective subscribers but when we were approached to integrate the two databases, we immediately saw the bigger picture and recognised the significant benefits this could bring to a wider audience of UK veterinary practices.
"The national database uses open standards for data collection and data is accepted from all practices irrespective of which practice management system they use. We believe it is the right thing to do for veterinary practices and brings significant benefits to the whole veterinary profession."
Practices are urged to subscribe to the PI or MAI services either independently or through one of their practice development partners. Although run from a common database each service will continue to be provided with its own unique features.
For further information on Performance Index practices should contact their Pfizer Account Manager, email Pfizer at Vetsupportplusuk@pfizer.com.
For further information on MAI, practices should contact Central Veterinary Services at mai@centralvet.com, or telephone 01359 245310
BCF Technology has launched a series of free canine X-ray positioning guides which are now available to download from www.bcftechnology.com.
The company says the guides are designed to provide a quick, easy-to-use reference to help you get the best radiographic views possible, every time.
BCF in-house radiographer Kat Evans said: "At BCF, we understand that capturing a great X-ray isn't just about having the best equipment; good positioning is crucial, these easy-to-use guides will help vets and vet nurses to create the very best radiograph."
BCF in-house vet Ben Sullivan added: "At BCF we are committed to improving the standards of radiography in the veterinary profession. We aim to help our customers make the very most of their equipment. This is why we are committed to supporting ongoing education and training. You will find a huge range of learning materials on our website aimed at helping you to develop further your veterinary ultrasonography and radiography abilities.
Full small animal and equine positional guides are in-built into the software of all CR X-ray systems available from BCF.
For more information, visit www.bcftechnology.com or call +44(0)1506 460 023.
PhotonUVC Vet is a non-contact treatment which emits low dose ultraviolet C light at a targeted area.
Photon Therapeutics says the device kills bacteria, viruses, fungi and other infecting organisms while being safe to host tissues.
Other claimed benefits of the device are that it avoids client compliance issues associated with eye-drops, it eliminates the need for antibiotic eye drops, and it is very simple to learn how to use.
The device costs £4,995.
To explain more about The PhotonUVC Vet, Dr. Simon Dean. MBChB, MSc, FRANZCO, FBCLA Chief Scientific Officer at Photon Therapeutics, and Dr. Mark Leddy BVSc, MBA, CEO, will be delivering a CPD presentation at the Exhibitor Showcase Theatre 3: "5 Amazing Seconds – A New Transformative Treatment for Corneal Infections", on Thursday 14th November at 3pm.
There is also a launch event reception at the stand from 16.15 to 18.15 on Thursday 14 November.
https://photon-therapeutics.com/
Boehringer Ingelheim Vetmedica has added a cardiology CPD section to its Vetmedin website. The section also includes a number of owner education resources to be used in practice.
The site, which is billed as a one-stop-shop on canine heart disease, includes an interactive radiology viewer, the Vetmedin atlas of cardiac radiology, radiology interpretation and diagnosis, an interactive MVD seminar and online downloadable Vetmedin dosage calculator to assist veterinary surgeons in prescribing the optimum dose.
Owner education materials include an animation explaining how to monitor a dog's resting respiratory rate, a video about heart failure and downloadable charts to help owners monitor their dog's condition.
For further information, visit www.vetmedin.co.uk, contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
Matthew’s award is in recognition of his paper Approach to initial management of canine generalised epileptic seizures in primary-care veterinary practices in the United Kingdom, co-authored with Laurent Garosi, which was selected by the BSAVA Committee as being the most valuable to veterinary practice.
James’ study explored data collected as part of the Small Animal Veterinary Surveillance Network (SAVSNET) at the University of Liverpool.
In total, clinical records concerning 3,150,713 consultations (917,373 dogs) were collected and analysed from 224 UK veterinary practices.
This included the management of canine generalised epileptic seizures in 517 dogs up to 6 years of age.
The study concluded that 98% of dogs presenting for a single epileptic seizure were not started on long-term therapy, in accordance with the approach recommended by the International Veterinary Epilepsy Task Force (IVETF).
Other findings from the study included:
The paper also reported on factors potentially associated with prescription of ASDs.
It stated that dogs who presented for cluster seizures (more than one epileptic seizure in a 24-hour period) were more likely to be prescribed ASDs, or to be referred to a specialist, than dogs without cluster seizures.
Dogs that were neutered or microchipped were more likely to be started on ASDs following the initial presentation, perhaps suggesting that owners who take part in regular preventative healthcare prior to the onset of their dog’s seizures could be more willing to start therapy in the earlier stages of the disease.
In addition, more than half of dogs with cluster seizures were not prescribed any ASDs.
Given that the presence of cluster seizures is typically considered an indication to start long-term therapy by the IVETF, Matthew says this may be one aspect of seizure management that could be improved in primary care practice.
Regarding the choice of anti-seizure drugs (ASDs), imepitoin was more frequently prescribed than phenobarbital in response to cluster seizures.
But unlike phenobarbital, the paper highlighted that the market authorisation for imepitoin does not include the treatment of cluster seizures.
Therefore vets should be aware that the use of imepitoin for cluster seizures should be considered as “off-licence” - and has additional implications for obtaining informed consent.
Matthew said: “We believe this research contributes to an improved understanding of the current management strategies for canine epilepsy in general practice and how this compares to the current guidelines advised by the IVETF.
"Given the prevalence of epileptic seizures within the UK canine population, as well as the large proportion of dogs that will be managed entirely within general practice without referral to a neurologist, it is vital to ensure that the level of care being provided is optimal.
"We therefore hope that this research ultimately supports and guides general practitioners in their approach to canine epilepsy, thereby improving the quality of life of affected dogs and their owners.”
https://onlinelibrary.wiley.com/doi/epdf/10.1111/jsap.13543
Simon Wootton, Northern European Region CAG Marketing Manager at Idexx said: "It is widely accepted that 1 in 3 cats and 1 in 10 dogs will develop CKD. The adoption by IRIS of the Idexx SDMA™ renal function test is testament to its benefits, and should give vets much more time to intervene and prescribe an appropriate course of action to help improve longevity and quality of life in CKD patients."
Idexx has produced two new wall-charts for practices, intended to assist with the diagnosis, staging and treatment of CKD in dogs and cats. They are being distributed to all practices in the UK, and can also be downloaded from the Idexx website – www.idexx.eu or ordered from Idexx by ringing 00800 1234 33 99.
The new programme includes ten days of practical imaging sessions based at CPD Solutions' training centre in Studley near Birmingham, where participants will develop their existing imaging skills and learn additional techniques that they can use directly in small animal practice.
CPD Solutions says its PgCerts have unique benefits and key differences from other PgCert options available to vets, namely a strong emphasis on practical training (all attendance days are practical, with no lecture days), the way the attendance days are grouped into three sessions for convenience, and the 12 month duration of the programme.
Susie Coughlan, veterinary surgeon and MD at CPD Solutions has 21 years’ experience in providing practical training for vets. ‘Our experience is that vets get the most out of hands-on practical training in a structured and supportive environment, combined with reflective application of their new skills in practice. The new PgCert in Small Animal Diagnostic Imaging follows the same format – all attendance sessions are practical, and the course provides support for developing reflective work based learning that vets can use with all of their patients.’
For more information, contact CPD Solutions on 0151 328 0444 or visit www.pgcert.com
The Committee had found Dr Elefterescu guilty of serious professional misconduct in relation to a number of charges which covered issues such as dishonesty, poor record-keeping, and failure to carry out adequate clinical examinations.
The full charges and findings of the RCVS Disciplinary Committee can be found at: www.rcvs.org.uk/disciplinary.
The Judicial Committee of the Privy Council held the appeal hearing in October last year with three Justices of the Supreme Court - Lord Kerr, Lord Carnwath and Lord Kitchin – comprising the Board.
The basis of the appeal to the Privy Council was that the Committee’s findings on the facts of the case were flawed, with his counsel saying that Dr Elefterescu 'strenuously disputes the findings by the Committee of his dishonesty and lack of professional competence and submits that there is no adequate basis for them in the evidence’.
His counsel also told the Board that the Disciplinary Committee’s sanction failed to take into account mitigating factors and that the decision to remove Dr Elefterescu from the Register was disproportionate.
In relation to the appeal against the Disciplinary Committee’s findings on the facts, the Board was not persuaded by any of the arguments put forward on behalf of Dr Elefterescu. These arguments included that the RCVS had failed to call relevant witnesses and had failed to make Dr Elefterescu aware of the significance of some evidential matters, disclosed to him.
In respect of the sanction, the Board was also unpersuaded by the arguments put forward by Dr Elefterescu’s counsel, namely that it was too harsh in its assessment of aggravating factors, did not give adequate weight to mitigating factors, and that it failed to distinguish lack of competence from misconduct.
In its judgment on the arguments put forward by Dr Elefterescu’s counsel, the Board said: "It is the opinion of the Board that these criticisms are not well founded. The Committee considered with care Dr Elefterescu’s proven and admitted conduct in relation to each of the charges and whether it fell below or far below the standard to be expected. It is to be noted in this regard that a number of the charges which were either admitted or upheld were not the subject of any challenge on this appeal.
"Overall, the Committee found that Dr Elefterescu’s clinical failures were very serious, involved failures in the basics of animal care, resulted in animal suffering and involved widespread breaches of the respondent’s [RCVS] code of professional conduct. It also expressed particular concern about its findings of dishonesty, and rightly so. That conduct was, in its view, ‘at the top end’ of disgraceful conduct in a professional respect. What is more, Dr Elefterescu had a lack of insight into his failings and a wholly unjustified confidence in his abilities which constituted an ongoing risk to animal welfare."
"These were findings which the Committee was clearly entitled to make and, in the light of them, the Board is firmly of the view that the decision of the Committee to direct the removal of Dr Elefterescu’s name from the Register cannot be impeached. The Board rejects the criticisms made of the Committee’s reasoning and the conclusions to which it came. The direction that Dr Elefterescu’s name must be removed from the Register was appropriate and proportionate."
The Judicial Committee’s full findings can be found at www.jcpc.uk/cases/docs/jcpc-2018-0060-judgment.pdf.
Ceva Animal Health has introduced an improved version of Hepatosyl, its liver support supplement for horses.
Hepatosyl Plus for horses contains the same antioxidant ingredients as the original version but now also contains Silybin, the most active isomer of Silybum marianum (milk thistle)1.
According to Ceva, the addition of Silybin gives new Hepatosyl Plus a triple antioxidant approach to liver support to help neutralise free radicals within the liver. Free radicals are produced by hepatocyte mitochondria and cause oxidative damage to cell membranes, protein and DNA.
The company says Hepatosyl Plus's triple approach includes S-adenosylmethionine (SAMe), in a stable, pure and absorbable form, which is converted into the potent liver anti-oxidant glutathione and also helps to maintain bile flow; Vitamin E, which is well-known as a potent liver antioxidant, and Silybin, which works as an antioxidant by increasing cellular superoxide dismutase.
Hepatosyl Plus remains the only liver supplement to contain Vitamin K which is needed by the liver for the production of many essential clotting factors, such as factors II, VII, IX and X, making it ideally suited for pre and post anaesthetic liver support.
Ceva says an independent trial2 on horses with confirmed liver disease has demonstrated the benefits of Hepatosyl. Conducted by European Specialist in equine internal medicine Dr Tim Brazil, the trial involved seven horses of various ages and types. All animals were given Hepatosyl in addition to treatment with antimicrobials, corticosteroids, a low protein diet and vitamin B supplementation. Post SAMe supplementation tests revealed a notable reduction in raised liver enzymes, serum proteins and bile acids and the seven horses showed obvious improvements including better appetite, weight gain and demeanour.
For further product information contact Ceva Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
References1 Flatland B (2003) Botanicals, Vitamins and Minerals and the Liver2 Brazil T (2007) S-adenosylmethionine liver support supplement trial in horses
Petplan's Veterinary Awards are designed to celebrate the nation’s most outstanding vets, vet nurses, practices, practice managers and support staff who are nominated by their colleagues and clients for continually going that extra mile, keeping pets healthy and giving owners peace of mind.
The independent panel of judges said that Johanna's nomination stood out for her ability to create a balance between leading a practice which maintains incredibly high clinical standards along with a welcoming, caring ethos with patients at the heart of everything they do.
Johanna said: "I’m absolutely ecstatic! I wasn’t expecting to win at all, so this is a real surprise – I just want to say thank you to those who nominated and all my staff for supporting me every day. What a brilliant feeling!"
The other big winner on the night was 387 Veterinary Centre. Two members of staff, Nicky Smith RVN and Joanne Civil, won 'Veterinary Nurse of the Year' and 'Veterinary Practice Support Staff of the Year' respectively, and the practice also took the overall 'Veterinary Practice of the Year' award.
'Veterinary Practice Manager of the Year' went to Anne Corson of Pennard Vets in Tonbridge.
Stronghold Plus contains the same selamectin found in common-or-garden Stronghold, licensed for the treatment of fleas, flea allergic dermatitis, ear mites (Otodectes cynotis), roundworm (Toxocara cati), intestinal hookworms (Ancylostoma tubaeforme), biting lice (Felicola subrostratus), and for the treatment of heartworm disease caused by Dirofilaria immitis.
To that has been added sarolaner, a new acaricide and insecticide which is also effective for five weeks against Ixodes ricinus, Ixodes hexagonus, and for four weeks against Dermacentor reticulatus and Rhipicephalus sanguineus.
Clint Lewis, Executive Vice President and President International Operations, said: "The launch of Stronghold Plus enables Zoetis to offer veterinarians in the European Union a new topical choice that treats the parasites commonly presenting a threat to cats with one convenient monthly dose.
For the first time, we have combined our new, versatile parasiticide sarolaner with the active ingredient in Stronghold, selamectin, resulting in the first approval of sarolaner for use in cats. We see sarolaner as a promising platform for future product lines and lifecycle innovations and are pleased with the positive data that sarolaner and its combination continue to generate in studies.”
Domenico Otranto, Professor of Parasitology at Bari University in Italy, who has reviewed the product data of Stronghold Plus, said: "A number of laboratory and field studies show the efficacy of the single spot-on application of Stronghold Plus for at least one month. Veterinarians in Europe now have a very effective option for the treatment and control of four prominent species of ticks commonly found on cats while maintaining proven efficacy against fleas, GI worms, heartworms, ear mites and lice. Ultimately, pet owners and practitioners have a new tool for improving health and welfare of cats."
Animalcare has announced the launch of Clavubactin (amoxicillin/clavulanate) for dogs and cats, presented as 4-way split tablets in three strengths to ensure optimum dosing. The three strengths (Clavubactin 50, 250 and 500) contain 50/12.5, 250/62.5 and 500/125mg of amoxicillin and clavulanic acid respectively. Clavubactin 50mg is licensed for cats and dogs. The 250 and 500mg formulation is licensed for dogs only.
According to the company, the increased combined level of active ingredients, compared to some other clavulanate-amoxicillin products on the market, achieves recommended target weight dosing (doses always kept at 12.5mg/kg), even with animals of greater weight, minimising the risk of underdosing.
The 4-way split tablets are designed to facilitate easy and accurate dosing of all sizes of dogs and cats, from 1kg bodyweight (¼ tablet Clavubactin 50) to 50kg (1 tablet Clavubactin 500) and above.
The tablets come in aluminium blister strips of ten tablets in five packaging presentations (Clavubactin 50 and 250 are available in 100 and 250 tablet packs and Clavubactin 500 in 100 tablets).
Animalcare Product Manager Tony Liepman said "Clavubactin allows for optimum target weight dosing and together with the accuracy enabled by SmartTabs easy 4-way split, this gives peace of mind to both vet and client."
The product is supported by dosage charts and dispensing envelopes (the latter is available on request).
For further information contact Animalcare on 01904 487687, speak to your regional Animalcare representative or visit www.animalcare.co.uk/contact-us.
Achieved by VMG members who have demonstrated an ability to effectively manage a veterinary practice, hospital or unit, the CVPM is aimed at experienced managers and members of the veterinary team in a leadership or management role. The qualification tests the knowledge of candidates in areas including management, HR, communication, marketing and financial planning.
VMG Director Georgina Hills (pictured right) said: "Effective veterinary leaders require expertise in all aspects of running a successful business, as well as a deep understanding of the veterinary sector and the CVPM is unique in testing their knowledge across the board. It is increasingly recognised as a benchmark for excellence and we are delighted to have seen an uplift in applications last year."
Further details on the CVPM and the application form are available here: https://www.vetmg.com/education/cvpm/
Eskimo, a reindeer at Edinburgh Zoo has received life-saving surgery just in time for Christmas, making him the first reindeer in history to receive keyhole surgery.
Vet Romain Pizzi successfully removed one of Eskimo's testes, which had been lodged in its abdomen since birth, using specialist surgical instruments donated to the zoo by one of Ark Surgical's strategic partners Surgical Innovations.
The zoo was worried that the retained testicle may have been developing into a tumour giving off abnormal hormones, and that this could become life-threatening. Thankfully, zoo surgeons found that the retained testicle, although abnormally sized, had not yet developed a tumour.
It is thought that the abnormal testicle was affecting Eskimo's production and flow of testosterone and, as a result, he was showing submissive behaviour and being bullied by the other male reindeer in the herd. He had also started to show some abnormal and delayed antler growth and development. Removing the testicle will halt any abnormal hormone production so hopefully Eskimo will return to full vigour just in time for Christmas.
Gavin O'Brien, Director at Ark Surgical said: "We were only too happy to help when Romain mentioned the challenging operation faced by Eskimo and in the season of goodwill we approached Surgical Innovations who kindly donated the instruments for this pioneering surgery."
Although laparoscopic surgery is routine in humans, the standard procedure in animals is still open abdominal surgery. Open abdominal surgery is 20 years behind human medical advances and has a number of negative factors on animals such as more post-operative pain, slower recovery and a higher risk of post-operative complications and infections.
Romain, a veterinary surgeon for the Royal Zoological Society of Scotland, based at Edinburgh Zoo, said: "Laparoscopic surgery is still very uncommon in veterinary medicine, even amongst common species such as dogs, cats and horses, so for keyhole surgery to be carried out on a reindeer shows a great advancement in veterinary surgery."
It is estimated that nearly one out of every two households in the UK are pet owners. Veterinary surgeons perform on average 600,000 open abdominal procedures annually but it is believed that less than 1% of vets currently practice laparoscopic surgery.
Romain believes that with the right instrumentation available through innovative companies such as Ark Surgical, UK vets now have more opportunity than ever to introduce laparoscopic techniques as part of their operating procedures.
Romain said: "This procedure was only really possible thanks to a cutting-edge designed retractor which we were able to use in this case. Ironically although a reindeer is a reasonably large animal, due to their unique anatomy and massive four chambered stomach that takes up most of the space in the abdomen, there is a very limited internal operating space. For this reason the operation was much more difficult than in a human, or in a dog, where there is more space to work, despite their smaller size."
"We were especially pleased with how quickly Eskimo recovered after surgery, he was standing and happily eating lichen again within 10 minutes of recovery from anaesthesia. He hardly seemed to notice he had even had surgery, although he was still slightly groggy from the anaesthesia. This would simply not have been possible with traditional open abdominal surgery, as the long wound would have been much more painful and debilitating."
The minimally invasive nature of laparoscopic surgery means there are numerous benefits for animals such as a reduction in post-operative pain, a faster recovery and reduced post-operative care. It also has a decreased risk of infection after surgery and a lower risk of any wound complications.
For veterinary surgeons laparoscopic surgery can offer better visualisation of the operated area, allowing them to be more precise and reach areas that are difficult to see in open surgery such as the liver and pelvic canal.
Romain carries out laparoscopic operations on dogs, cats and exotic pets at his own veterinary practice Inglis Veterinary Centre (Scotland) and has pioneered several new laparoscopic techniques.
He said: "Laparoscopic surgery has so many benefits for the animal, the veterinary surgeons and the zoo, so there is no reason why it should not be more common practice within veterinary surgery. I hope Eskimo's experience helps raise its profile and encourage more veterinary surgeons to look in to it as a standard surgical procedure."
Ark Surgical offers a wide range of laparoscopy instruments and peripherals to vets across the UK and to suit all budgets. The company says it is already working with many of the UK's leading vets and agencies such as the Royal Zoological Society of Scotland, as well as the UK foremost laparoscopic medical device manufacturer Surgical Innovations, to be at the forefront of veterinary laparoscopic surgery
For more information on animal laparoscopic surgery contact Ark Surgical on 01732 862882 or http://www.arksurgical.co.uk/
The organisations made a joint submission to the Migration Advisory Committee (MAC) as part of its review into the Shortage Occupation List which began in autumn 2018 and will report back in spring 2019.
The BVA and the RCVS had previously made calls for the profession to be added to the list in 2017 when the MAC held a call for evidence on the impact of the UK's exit from the EU on various professions. The latest submission is a development on this previous submission, focused on the need for the post-Brexit immigration system to recognise the issues affecting the veterinary workforce, which is already under-capacity, and reiterating its importance in areas such as public health, food safety, disease surveillance and control, education, research, clinical practice and animal welfare.
The submission details how the demand for veterinary services does not currently match supply and that the UK is therefore reliant on overseas registrants, particularly from the rest of the EU, who currently make up around 50% of new registrants in a given year.
The RCVS and BVA add that, in the post-Brexit immigration system, this reliance on overseas vets needs to be recognised by adding veterinary surgeons to the Shortage Occupation List, thus reducing the immigration requirements needed for overseas veterinary surgeons to live and work in the UK and streamlining the application process for employers.
Amanda Boag, RCVS President, said: "We wanted to use this submission as an opportunity to reiterate the circumstances currently facing the profession, particularly in light of the uncertainties around the UK’s exit from the EU and the impact this could have on the supply of veterinary workforce from the rest of the EU, which is crucially important in a number of areas. We need, therefore, for veterinary surgeons to be immediately added back to the list so that we can ensure that this flow of workforce continues and that animal health and welfare is protected.
"In the meantime we are continuing to work with BVA and the Department for Environment, Food and Rural Affairs (Defra) to look at how we can develop ‘home-grown’ veterinary capacity in the UK through expanding the UK veterinary education sector, increasing retention rates within the profession, and looking at how the veterinary team could be reformed to allow allied professionals, such as veterinary nurses, to take on extra tasks and free up veterinary time. However, these are all long-term projects and not quick fixes to the issues facing the profession."
As well as calling for a future immigration system to prioritise the veterinary profession, RCVS and BVA also recommend that veterinary employers be exempt from the Immigration Skills Charge to avoid additional barriers or burdens to the employment of overseas vets and recommend that there is no minimum earning cap for veterinary surgeons applying for work visas, on the basis that veterinary surgeons are "skilled professionals who may choose to work in the UK for reasons other than remuneration".
Simon Doherty, BVA President, said: "It is in MAC’s gift to reinstate vets on the Shortage Occupation List and this evidence makes a strong case for it to happen as quickly as possible.
"Vets deliver multiple benefits to animal health and welfare, public health and food safety, and they have a crucial role to play in future trade deals and keeping standards and confidence in UK exports high. The profession is also indebted to a high proportion of skilled EU vets who have chosen to make the UK their home and place of work.
"With this in mind, the future immigration system must be geared around preserving veterinary capacity rather than introducing new layers of bureaucracy or restrictions on flexible movement between roles. We have raised concerns that extending the Immigration Skills Charge to EU workers would hit some areas of the workforce disproportionately hard, particularly the abattoir industry where 95 per cent of Official Veterinarians hail from overseas.
"With uncertain times ahead and demand for some veterinary services predicted to spiral after Brexit, it has never been more pressing to take decisive action to safeguard against shortfalls in capacity and give a vital vote of confidence in the veterinary workforce."
To read the full submission, visit https://www.rcvs.org.uk/document-library/joint-rcvs-and-bva-submission-to-migration-advisory-committee/
Mr Samuel had been removed from the Register in 2018 for causing unnecessary harm to numerous animals.
After being tried and convicted of several animal welfare offences alongside his former partner at Leeds Magistrates Court, Mr Samuel was sentenced to 12 weeks’ imprisonment, suspended for 12-months on the condition that he did 150 hours of unpaid work.
He was also ordered to pay a £100 fine and subjected to a disqualification order under the Animal Welfare Act for three years.
Mr Samuel’s application for restoration was based on the facts that he accepted the seriousness of his actions and that he did not challenge the DC’s 2018 decision.
The Committee also heard evidence that since his removal from the Register, Mr Samuel - who had run a first opinion veterinary practice for nine years prior to being struck off - has undertaken 340 hours of work experience with other veterinary surgeons and 20 hours of CPD.
Dr Samuel was represented by Counsel who outlined in his submissions to the Committee how Dr Samuel’s former partner had sole responsibility for the animals and that she was involved in rehoming dogs and cats and that their relationship was ‘stressful’, that this made Dr Samuel neglect his professional obligations, and that Dr Samuel was now in a different relationship and his life had been ‘transformed’ since his conviction.
The College opposed Dr Samuel being restored to the Register.
Ms Curtis, Counsel on behalf of the College, submitted to the Committee that Dr Samuel continued to represent a risk to the welfare of animals and that to allow him to be restored to the Register would undermine public confidence in the profession.
She explained that even though his sentence and Animal Welfare Act Disqualification Order had come to an end, and he was now legally able to own animals, this should not be equated with him now being fit to return to the Register.
Dr Austin Kirwan MRCVS, chairing the Committee, and speaking on its behalf, said: “Where a veterinary surgeon has shown himself to be capable of such indifference to the welfare of multiple animals, there remained, in the Committee’s view, a real risk of that indifference manifesting itself again.
"A registered veterinary surgeon is entrusted with the care of animals, often when they are at their most vulnerable, and sometimes for prolonged periods of time.
"Given the nature of the animal welfare offences committed by Dr Samuel, the Committee considered there would be a real and significant risk to animals if the high level of responsibility and trust that comes with registration were returned to him.
“For a veterinary surgeon, conduct involving neglect of animals is at the highest end of the spectrum of serious professional misconduct.
"For the reasons outlined above, the Committee considered Dr Samuel continued to represent a risk to animal welfare and thus allowing him to be restored to the Register would seriously undermine public confidence in the profession.
"For all these reasons the application to restore Dr Samuel to the Register is refused.”
The Committee’s full findings can be viewed at www.rcvs.org.uk/disciplinary
The announcement came hot on the heels of announcements from Ceva and Boehringer that they too had vaccines in the pipeline.
Syvazul BTV3 is licensed to reduce viraemia, prevent mortality and reduce clinical signs and lesions in sheep and for the active immunisation against bluetongue virus serotype 3 in cattle.
Like all vaccines currently available for this serotype, the vaccine will not prevent infection and vaccinated animals will still be subject to bluetongue movement controls and trade restrictions currently in place.
Administered as a single 2ml dose subcutaneously in sheep and as two 4ml intramuscular doses 3 weeks apart in cattle, Syvazul BTV3 contains inactivated Bluetongue virus, serotype 3 (BTV-3), strain BTV-3/NET2023.
The vaccine is licenced for use during pregnancy and lactation in both sheep and cattle.
The onset of immunity is 28 days after the primary vaccine in sheep. A single booster revaccination dose of 2ml for sheep and 4ml for cattle is recommended after 12 months.
Presented in two pack sizes, 80ml and 200ml, Syvazul BTV3 vaccine has a shelf life of 2 years from manufacture and a broach life of 10 hours.
Licensing for use will be geographic, based upon high risk counties or by specific licence from the APHA.
A campaign to reform English libel law to allow for robust criticism of scientific and medical claims without fear of legal action has been launched by journalist and author Simon Singh. It's a campaign which anyone working in the caring professions might wish to support.
The campaign comes as a consequence of legal action taken against Mr Singh by The British Chiropractic Association, which took exception (perhaps unsurprisingly) to an article he'd written in The Guardian. In the article, Mr Singh denounced claims on the BCA website that its members could use spinal manipulation to treat children with colic, ear infections, asthma, sleeping and feeding conditions, and prolongued crying as 'bogus', and criticised the BCA for 'happily promoting' these claims.
Out of curiosity, VetSurgeon rang the BCA press office this morning, and asked to be given the references for studies which it feels would support the original claims made on its site. Non have been forthcoming so far, which is a surprise. Under the circumstances, we'd have expected the BCA would have a raft of supporting evidence readily available.
But this isn't really about whether or not chiropractic works or not. The case seems to hinge upon whether Mr Singh's article implied that the BCA was being deliberately dishonest, or just delusional. He say's the latter. Unfortunately for him, Mr Justice Eady recently ruled the former, leaving Mr Singh with a bill for £100,000 worth of legal fees.
Mr Singh is to appeal. At stake is the freedom to be able to challenge scientific claims without fear of being sued. If you'd like to support this campaign, visit senseaboutscience.com and add your name to the 7000 others (including some pretty illustrious names) who have already done so.
The company says the new range performs as well as the leading brands and delivers consistently reliable sterilisation, but at a much lower price point than the market has seen before. The entry level 8 Litre machine retails at £1,100.
The Yeson machines range in size from an 8 litre to a 22 litre capacity and offer quiet Class B operation, 7 pre-set sterilisation programs, B&D Helix testing and a choice of printer or USB reporting.
Yeson UK MD Will Thomas said: "The autoclave market has been dominated by a few major players for many years and until now they’ve been largely unchallenged. Many people are now asking “why should I pay thousands more for a utility machine such as an autoclave? We’re just hoping that we can meet the demand."
For more information, visit www.yeson-uk.com
Described as a first-of-its-kind, mobile-enabled digital whitepaper, the publication offers veterinary surgeons and farmers a resource on ketosis, scientific insights on the impact of the disease, and tools to help optimize dairy herd management.
According to the company, the whitepaper reveals that ketone bodies play a more significant role in metabolic diseases than was previously realized, and that beta-hydroxybutyrate is a good indicator of the presence of subclinical ketosis in dairy cattle.
Rinse Boersma, Dairy Species Manager, Animal Health, Bayer said: "Recognizing the significance of ketone bodies is a positive step towards further enhancing dairy cattle health and welfare. Veterinarians can now reliably detect the presence of subclinical ketosis in dairy herds with a simple blood test, and act quickly with the appropriate corrective measures to arrest disease progression."
Also at Congress, Bayer revealed its enhanced BCS Cowdition smartphone application, designed to support ease and accuracy of body condition scoring (BCS) of dairy cows. Bayer says the upgrade helps farmers to improve herd health management by enabling assessment of individual cows’ BCS scores based on its lactation cycle, alerts for cows that need to be attended to, and a dashboard that offers farmers an overview of their entire herd’s health.
BCS Cowdition is available in 10 languages and is free for download from the AppStore and GooglePlay.
The company says Cevaprost can help improve breeding success in reproduction protocols in cattle and has the following indications:
Ceva says these indications are equivalent to those of the leading racemic and single isomer cloprostenols available in the UK.
Cevaprost is available in a 20ml colourless glass vial and in a multi-pack of 10 x 20ml vials. It can be administered in single or repeated 2ml doses (equivalent to 0.5mg of cloprostenol) by intramuscular injection. It has a withdrawal period of one day for meat and no withdrawal period for milk.
Peter Keyte, ruminant business unit manager at Ceva Animal Health, said: “We are delighted to add Cevaprost to our extensive range of reprodAction products to provide vet and farmers with comprehensive cattle reproduction solutions and improve breeding success in reproduction protocols.”
For further information, contact your local Ceva territory manager or email cevauk@ceva.com.
The Royal College of Veterinary Surgeons is warning veterinary surgeons to be on their guard after it came to light that a fraudster is charging a £150 'non-refundable application fee' for an RCVS 'internship' which does not exist. Apart from anything else, the RCVS does not offer internships.
Information about the fake internship has been sent to individuals registered with German website http://www.vetcontact.com/. It includes details about the Royal Veterinary College and the RCVS, but is basically fiction. It refers to a made up 'RCVS Hospital' in the 'Flint Hills of London'.
Gordon Hockey, RCVS Head of Professional Conduct said: "So far, only a handful of veterinary surgeons - all based overseas - have contacted us regarding the internship and queried the request for a non-refundable 'application' fee, although we are concerned that others may have been caught out.
"We would advise any veterinary surgeon to think twice before paying for a third party to facilitate an application for any placement or internship, and reiterate that the RCVS does not offer any such programmes."
The College is following up the situation with http://www.vetcontact.com/ and, if appropriate, will notify the police. In the meantime, anyone who is concerned that they may have fallen victim to the hoax should contact the RCVS Professional Conduct department on 020 7202 0728.
The BVA Board oversees the performance of the Association and is responsible for corporate and financial governance and for setting the BVA’s strategic direction. It consists of nine members: the three Officers of the BVA, four Directors appointed by BVA Council and up to 2 non-veterinary Directors appointed by the Board. The Chairman is elected by the Board.
Philip, a Bristol University Veterinary School graduate, spent seven years in mixed practice in Sussex, Kent and Suffolk before embarking on a career in the veterinary pharmaceutical industry.
He became CEO of Novartis Animal Health UK Ltd in 1996 (where, incidentally, he was ultimately responsible for signing up a wet-behind-the-ears PR consultant by the name of Arlo Guthrie and giving the go-ahead for the development of vetnurse.co.uk, which in turn led to the launch of vetsurgeon.org). In 2003 he became the company's Head of Global Marketing, and in 2005, Head of Global Business Development.
Philip has also run business elective training at the Royal Veterinary College, which has provided first-hand experience of the concerns and opportunities facing new graduates within a changing profession.
Gudrun Ravetz, President of the British Veterinary Association, said: "We are delighted to announce Philip Lowndes as the new Chairman of the BVA Board. His experience and expertise in business, knowledge of the veterinary profession and involvement with BVA will be of great value as we continue to grow our membership and expand our services and support for vets, especially during the uncertainty caused by Brexit."
Philip holds previous chair experience, as Chairman of the National Office of Animal Health (NOAH) between 1997-2004, and currently sits as Chairman of both the Novartis UK Pension Trustee Board and its Investment Committee. He joined BVA’s Board in 2013 and was re-elected by BVA Council for a second term in 2016. He will be taking over from Derek Williams, who stepped down in March after seven years of tireless work as Chairman.
Gudrun said: "I also want to take this opportunity to thank Derek Williams for all the hard work he has put in over many years. In his role as Chairman Derek’s experience and expertise have been vital in helping BVA grow as an organisation."
Philip said: "I am honoured to be elected as the next Chairman of the BVA and look forward to chairing the Board as it addresses the challenges ahead. The veterinary profession needs and deserves vibrant representation and it is the Board’s role to ensure that the organisation has the ability and the resources to achieve this to the benefit of our membership."
The BVA Board also gained a new non-veterinary Board Director, Steven Anderson Dixon, from April. Mr Dixon brings with him a successful career in newspaper and magazine publishing, which will be an asset as BVA consolidates and continues to develop its portfolio of veterinary journals.
Vet Futures, the joint initiative by the RCVS and BVA to stimulate debate about the future of the profession, has opened a new discussion hospice care, and whether it it will become mainstream in veterinary medicine.
This month's Vet Futures guest blogger, Kath Dyson, a former veterinary surgeon who qualified from Glasgow in 1989, writes that veterinary palliative care, while a relatively recent phenomenon, has been growing in stature, particularly in the United States, with symposia and conferences on the subject as well as webinars and chapters in text books.
She notes the increasing number of UK vets offering hospice care, highlighting the differences between palliative services offered in human and veterinary medicine as well as debates within the profession over the advantages and disadvantages of palliative care versus euthanasia.
She said: "In animal hospice it is the pet's owner who takes on all the financial, practical and emotional costs involved, whereas human patients have a lot more support available. Euthanasia is always an option in veterinary medicine, and indeed euthanasia of an animal can legally be carried out by anyone, so long as it is done humanely."
On the euthanasia debate she adds: "Some regard euthanasia as more of a last resort, with hospice assisted natural death being seen as more preferable and only a minority of patients requiring euthanasia. Others feel that euthanasia is more often likely to be the preferable outcome of a period of hospice care in the animal patient, even though they do not rule out a natural death."
Overall she argues that additional expertise from veterinary surgeons in end of life care will help the profession be "even better able to provide truly lifelong care to all their animal patients".
To accompany Kath Dyson's article, this month's poll asks if hospice care will become a standard part of practice.
Last month's poll asked if vets are given adequate information, guidance and support on ethnic and cultural diversity in relation to a blog written by a British Asian vet about prejudice he encountered from a client. The vast majority (90%) of the 118 people who responded to the poll thought that the profession was lacking in support when it came to diversity. Diversity in the profession and how to increase it has been a key topic identified by the project and it will be one of the issues addressed in the final Vet Futures Report published later this year.
To take part in this month's poll and to read and comment on Kathy Dyson's blog visit www.vetfutures.org.uk/discuss